A Phase 1 interventional study of JL18008 1 μg/kg and JL18008 5 μg/kg in HIV Infections, sponsored by Jecho Biopharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Jecho Biopharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.
Among the 67 studies in HIV Infections with a site in China, this one is the 40th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 64th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:
Liaoning Chengda Biotechnology CO., LTD · Sites in China
Ages 18–60
Jecho Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18–65
Shanghai Public Health Clinical Center · Sites in China
Ages 18+
Chinese University of Hong Kong · Sites in China
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 5 · Phase 3 11 · Phase 4 14
First in 2002; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 145 across the 50 interventional studies, 435 across the 16 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 67 have an industry lead sponsor. The 10 most frequent:
Jecho Biopharmaceuticals Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
Jecho Biopharmaceuticals Co., Ltd. has 2 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06830668National Center for AIDS/STD Control and Prevention, China CDCSame-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation | 2026-12-31 |
| NCT07579741Jecho Biopharmaceuticals Co., Ltd.A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders | 2027-02-12 |
| NCT07932132Liaoning Chengda Biotechnology CO., LTDImmunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 67 studies in HIV Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted in healthy adult volunteers to evaluate the safety and tolerability of a single injection of an investigational drug called JL18008. The study also examines how the body processes the drug and how it affects immune cells. Participants receive one intramuscular injection of either JL18008 at one of six dose levels (1, 5, 10, 20, 40, or 70 μg/kg) or a placebo (an inactive substance). The study is randomized, double-blind, and placebo-controlled, meaning participants and study staff do not know who receives the active drug or placebo. Blood samples are collected over 56 days to measure drug levels, immune cell counts (such as CD4⁺ T cells), and any antibodies that may form against the drug. The goal is to find a safe dose that can be tested in future studies of people with HIV who have low CD4⁺ T cells despite antiviral treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intramuscular injection of JL18008 at 1 μg/kg.
Drug: JL18008 1 μg/kg
Single intramuscular injection of placebo (JL18008 buffer).
Drug: Placebo (for 1 μg/kg Group)
Single intramuscular injection of JL18008 at 5 μg/kg.
Drug: JL18008 5 μg/kg
Single intramuscular injection of placebo.
Drug: Placebo (for 5 μg/kg Group)
Single intramuscular injection of JL18008 at 10 μg/kg.
Drug: JL18008 10 μg/kg
Single intramuscular injection of placebo.
Drug: Placebo (for 10 μg/kg Group)
Single intramuscular injection of JL18008 at 20 μg/kg.
Drug: JL18008 20 μg/kg
Single intramuscular injection of placebo.
Drug: Placebo (for 20 μg/kg Group)
Single intramuscular injection of JL18008 at 40 μg/kg.
Drug: JL18008 40 μg/kg
Single intramuscular injection of placebo.
Drug: Placebo (for 40 μg/kg Group)
Single intramuscular injection of JL18008 at 70 μg/kg.
Drug: JL18008 70 μg/kg
Single intramuscular injection of placebo.
Drug: Placebo (for 70 μg/kg Group)
Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 1 μg/kg.
Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 5 μg/kg.
Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 10 μg/kg.
Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 20 μg/kg.
Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 40 μg/kg.
Recombinant human serum albumin/human interleukin-7 fusion protein (JL18008). Supplied as a solution for injection at 2.5 mg/mL. Administered as a single intramuscular injection at a dose of 70 μg/kg.
JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 1 μg/kg.
JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 5 μg/kg.
JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 10 μg/kg.
JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 20 μg/kg.
JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 40 μg/kg.
JL18008 injection buffer (contains the same excipients as the active drug without the active ingredient). Supplied as a solution for injection. Administered as a single intramuscular injection at a volume matching the active dose of 70 μg/kg.
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI CTCAE v5.0
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs). AEs graded according to NCI CTCAE version 5.0. Assessed from Day 1 through Day 56.
Time frame: Up to 56 days
Change from Baseline in White Blood Cell Count (WBC)
Change from baseline in white blood cell count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Neutrophil Count (NEUT)
Change from baseline in neutrophil count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Eosinophil Count (EOS)
Change from baseline in eosinophil count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Basophil Count (BASO)
Change from baseline in basophil count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Lymphocyte Count (LYMPH)
Change from baseline in lymphocyte count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Red Blood Cell Count (RBC)
Change from baseline in red blood cell count. Measured in 10¹²/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Hemoglobin (HGB)
Change from baseline in hemoglobin. Measured in g/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Platelet Count (PLT)
Change from baseline in platelet count. Measured in 10⁹/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Hematocrit (HCT)
Change from baseline in hematocrit. Measured as a percentage (%). Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Total Bilirubin (TBIL)
Change from baseline in total bilirubin. Measured in μmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Total Protein (TP)
Change from baseline in total protein. Measured in g/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Albumin (ALB)
Change from baseline in albumin. Measured in g/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Alanine Aminotransferase (ALT)
Change from Baseline in Alanine Aminotransferase (ALT)
Time frame: Up to 56 days
Change from Baseline in Aspartate Aminotransferase (AST)
Change from baseline in aspartate aminotransferase. Measured in U/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Gamma-Glutamyl Transferase (γ-GT)
Change from baseline in gamma-glutamyl transferase. Measured in U/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Creatinine (Cr)
Change from baseline in creatinine. Measured in μmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Total Cholesterol (TCHO)
Change from baseline in total cholesterol. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Triglycerides (TG)
Change from baseline in triglycerides. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Blood Urea Nitrogen (BUN)/Urea
Change from baseline in blood urea nitrogen. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Alkaline Phosphatase (ALP)
Change from baseline in alkaline phosphatase. Measured in U/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Blood Glucose (GLU)
Change from baseline in blood glucose. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Serum Phosphorus (Pi)
Change from baseline in serum phosphorus. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Serum Sodium (Na⁺)
Change from baseline in serum sodium. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Serum Potassium (K⁺)
Change from baseline in serum potassium. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Serum Calcium (Ca²⁺)
Change from baseline in serum calcium. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Serum Magnesium (Mg²⁺)
Change from baseline in serum magnesium. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Serum Chloride (Cl-)
Change from baseline in serum chloride. Measured in mmol/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in International Normalized Ratio (INR)
Change from baseline in international normalized ratio. Unitless ratio. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Activated Partial Thromboplastin Time (APTT)
Change from Baseline in Activated Partial Thromboplastin Time (APTT)
Time frame: Up to 56 days
Change from Baseline in Prothrombin Time (PT)
Change from baseline in prothrombin time. Measured in seconds. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Fibrinogen (FIB)
Change from baseline in fibrinogen. Measured in g/L. Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in ECG Parameter: QTcF Interval
Change from baseline in the QT interval corrected for heart rate using Fridericia's formula (QTcF). Measured in milliseconds (ms). Assessed at baseline and on Days 2, 5, 8, 15, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Systolic Blood Pressure (SBP)
Change from baseline in systolic blood pressure. Measured in mmHg. Assessed at baseline and on Days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Diastolic Blood Pressure (DBP)
Change from baseline in diastolic blood pressure. Measured in mmHg. Assessed at baseline and on Days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, and 56.
Time frame: Up to 56 days
Change from Baseline in Pulse Rate
Change from baseline in pulse rate. Measured in beats per minute (bpm). Assessed at baseline and on Days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, and 56.
Time frame: Up to 56 days
Peak Plasma Concentration (Cmax) - Single Dose
Maximum observed plasma concentration following single intramuscular injection. Measured in pg/mL. Assessed at pre-dose and at 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose.
Time frame: Up to 672 hours after first dose
Time to Reach Peak Plasma Concentration (Tmax) - Single Dose
Time to reach maximum observed plasma concentration. Measured in hours (h). Same time points as Cmax.
Time frame: Up to 672 hours after first dose
Elimination Half-Life (t½) - Single Dose
Elimination half-life calculated as ln(2)/λz. Measured in hours (h).
Time frame: Up to 672 hours after first dose
Area Under the Curve from Time 0 to Last Measurable Concentration (AUC₀-ₗₐₛₜ) - Single Dose
AUC using linear trapezoidal rule. Measured in h·pg/mL.
Time frame: Up to 672 hours after first dose
Area Under the Curve from Time 0 to Infinity (AUC₀-∞) - Single Dose
Extrapolated AUC. Measured in h·pg/mL.
Time frame: Up to 672 hours after first dose
Area Under the Curve from Time 0 to 168 Hours (AUC₀-₁₆₈ₕ) - Single Dose
AUC from 0 to 168 hours post-dose. Measured in h·pg/mL.
Time frame: Up to 168 hours after first dose
Apparent Clearance (CL/F) - Single Dose
Dose divided by AUC₀-∞. Measured in L/h.
Time frame: Up to 672 hours after first dose
Apparent Volume of Distribution (Vz/F) - Single Dose
Dose divided by (λz × AUC₀-∞). Measured in L.
Time frame: Up to 672 hours after first dose
Change from Baseline in CD4⁺ T Cell Count
Change from baseline in absolute CD4⁺ T cell count. Measured in cells/μL. Assessed at baseline and at 24, 48, 72, 96, 120, 168, 240, 336, 504, 672, 1320 hours post-dose.
Time frame: Up to 56 days
Change from Baseline in CD8⁺ T Cell Count
Change from baseline in absolute CD8⁺ T cell count. Measured in cells/μL. Same time points as CD4⁺.
Time frame: Up to 56 days
Change from Baseline in CD4/CD8 T Cell Ratio
Change from baseline in the ratio of CD4⁺ to CD8⁺ T cells. Unitless ratio. Same time points as CD4⁺.
Time frame: Up to 56 days
Change from Baseline in Serum Interleukin-2 (IL-2) Level
Change from baseline in serum IL-2 level. Measured in pg/mL. Assessed at baseline and at 24, 48, 72, 96, 120, 168, 240, 336, 504, 672 hours post-dose.
Time frame: Up to 672 hours (28 days)
Change from Baseline in Serum Interleukin-4 (IL-4) Level
Change from baseline in serum IL-4 level. Measured in pg/mL. Same time points as IL-2.
Time frame: Up to 672 hours (28 days)
Change from Baseline in Serum Interleukin-6 (IL-6) Level
Change from baseline in serum IL-6 level. Measured in pg/mL. Same time points as IL-2.
Time frame: Up to 672 hours (28 days)
Change from Baseline in Serum Interleukin-8 (IL-8) Level
Change from baseline in serum IL-8 level. Measured in pg/mL. Same time points as IL-2.
Time frame: Up to 672 hours (28 days)
Change from Baseline in Serum Interleukin-10 (IL-10) Level
Change from baseline in serum IL-10 level. Measured in pg/mL. Same time points as IL-2.
Time frame: Up to 672 hours (28 days)
Change from Baseline in Serum Tumor Necrosis Factor-alpha (TNF-α) Level
Change from baseline in serum TNF-α level. Measured in pg/mL. Same time points as IL-2.
Time frame: Up to 672 hours (28 days)
Change from Baseline in Serum Interferon-gamma (IFN-γ) Level
Change from baseline in serum IFN-γ level. Measured in pg/mL. Same time points as IL-2.
Time frame: Up to 672 hours (28 days)
Number of Participants with Anti-Drug Antibodies (ADA)
Incidence of anti-drug antibodies (ADA) against JL18008. For ADA-positive participants, titers and neutralizing antibodies (Nab) will be assessed. Assessed at baseline and at 168, 336, 504, 672, 1320 hours post-dose.
Time frame: Up to 56 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2024 to primary completion in Aug 2025, 13 months.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 13 months is above that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jecho Biopharmaceuticals Co., Ltd. →